ArticleFrontiers in endocrinology2025
Estimates and projections of the global economic cost of breast cancers from 2021 to 2050.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phytochemicals from Agro-Industrial By-Products for Breast Cancer Prevention and Therapy: Molecular Mechanisms and Circular Bioeconomy Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Temporal Patterns of Breast Cancer-Related Sickness Absence and Social Insurance Expenditures Among Women in Poland, 2020-2024: A Nationwide Registry-Based Study.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To quantify the global macroeconomic burden of breast cancer in 2021, reveal disparities in economic losses across regions, age groups, and gender groups, and provide a basis for optimizing the allocation of prevention and control resources. Methods: Based on breast cancer disability-adjusted life years (DALY) data from the Global Burden of Disease (GBD 2021) database, combined with World Bank economic indicators, the value of lost welfare (VLW) model was employed to assess economic losses. The model standardized losses across countries using the statistical value of life (VSL), with a core parameter income elasticity of 1.0. Regional disparities were analyzed through stratification by Socio-demographic Index (SDI), and statistical uncertainty was calculated using a Bayesian model with 95% uncertainty intervals. Results: In 2021, the global VLW due to breast cancer reached 2,538.849 billion US dollars, accounting for 1.65% of global GDP. Regional analysis revealed significant inequality: High-income North America bore the highest economic loss (557.9 billion US dollars), followed by Western Europe (551.4 billion US dollars), while Central Europe, Eastern Europe, and Central Asia, despite lower absolute losses, had an economic burden as a proportion of GDP as high as 3.01%, far exceeding the global average. In terms of population distribution, the female group dominated absolutely (accounting for 24% of female cancer deaths), and economic losses for patients aged 50 and above accounted for over 70%, highlighting the characteristic burden of disease aging. The forecast indicates that the total VLW caused by breast cancer worldwide in 2050 will reach US$21,008.2 billion, with the top regions incurring the highest economic losses being South Asia, East Asia, High-income North America, and Southeast Asia. Conclusion: Breast cancer causes significant macroeconomic losses and exhibits marked regional inequality, with high-income countries bearing the highest absolute burden, while low- and middle-income regions face more severe relative economic impacts. It is imperative to implement targeted prevention and control strategies based on SDI stratification to promote optimal allocation of global health resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.